Zhongbo Juli Invests in AI Healthcare Innovator Null Hypothesis to Revolutionize Medical Content Production and Reshape Innovative Pharma Commercialization Ecosystem

VCBeat has learned that, recently,ZBJL CAPITALCompleted theNull Hypothesis Information Technology Co., Ltd. (hereinafter referred to as “Null Hypothesis”)investment. This round was led byVB CapitalServed as the exclusive financial advisor, with the funds raised to be primarily used for optimizing Zero Hypothesis's medical AI products and further advancing commercial collaborations with renowned pharmaceutical and medical device companies.

Over the past decade, newly approved drugs in China have accounted for 14% of the global total, while the number of clinical trial projects in China has reached one-third of the global share, second only to the United States. Innovative drugs have achieved remarkable progress in recent years. Meanwhile, emerging Chinese biotech companies have entered a phase of large-scale commercialization. In the next three to five years, they will face comprehensive tests across multiple dimensions, including capital markets, commercial performance, business development (BD), and global expansion.

“The Dilemma of ‘Innovation Without Revenue Generation’ Urgently Needs to Be Resolved:”The ultimate success of an innovative drug hinges on its commercial viability. Currently, the post-launch sales of core products for many innovative pharmaceutical companies fall far short of expectations. While commercialization is a matter of life and death for these enterprises, its importance, complexity, and associated challenges have only recently begun to receive due attention. How innovative pharmaceutical companies can navigate a stable commercialization path and effectively translate scientific innovations into commercial outcomes remains an urgent challenge for the entire industry.

Building an innovative commercialization system is fraught with challenges:The sales scenarios for innovative drugs differ significantly from those for traditional generic drugs. Characterized by a strong academic focus and high clinical complexity that varies from patient to patient, they require personalized, professional academic content tailored to individual needs. This dramatically increases the complexity of information processing and workflow management. Furthermore, it is necessary to achieve shifts in physicians’ perceptions within limited timeframes. Since the “product-centric sales” approach used for generic drugs fails to support physicians’ decision-making, a “solution-based” sales system will become the primary model for marketing innovative drugs.

Effective support of academic content is key to the commercialization system:Academic content is the sole foundation connecting pharmaceutical companies, physicians, and patients, serving as the core hub in the era of medical innovation. Pharmaceutical companies urgently need to establish a scalable, flexible, and efficient “academic content support system for innovative drugs” to ensure automation and high efficiency across the entire lifecycle of academic content—from design, production, and circulation to distribution and secondary utilization. This will enable marketing, sales, and other relevant personnel to communicate with physicians efficiently and accurately, rapidly achieving peak sales targets within limited timeframes.

Zero Hypothesis recognized the substantial demand for high-quality professional medical knowledge within the healthcare industry as early as 2019 and anticipated that AI technology would bring about significant transformation to the sector. Consequently, it proactively invested in the development of AI-enhanced medical search and AIGC products. Zero Hypothesis targeted top-tier multinational pharmaceutical companies and core physicians at leading Grade 3A hospitals as its entry point, combining general large language models with its proprietary specialized academic small models to build a world-class “Generative AI Engine for Medical Academic Content.”

Transforming the Traditional Acquisition, Integration, and Generation of Professional Knowledge with AI:By leveraging AI-powered tools for intelligent knowledge retrieval and content creation, Zero Hypothesis addresses the core demands of commercializing innovative drugs and medical devices—namely, the “high-quality integration” and “automated generation” of medical content. It enables the accumulation, organization, and utilization of medical content, reducing time costs from days or even weeks to just one day or a few hours, thereby significantly enhancing the work efficiency of professional medical knowledge workers.

Rebuilding Academic Interaction Between Enterprises and Physicians Through AI:Through Zero Hypothesis’s AI-powered products, pharmaceutical and medical device companies can gain deeper insights into physicians’ clinical needs and more efficiently and precisely deliver tailored content relevant to product strategy, market sales, clinical academia, and physician engagement. Meanwhile, physicians can access professional academic resources anytime and anywhere via the Zero Hypothesis platform, proactively obtain customized academic content provided by pharmaceutical companies, and quickly acquire the latest comprehensive information on complex and controversial issues. This significantly enhances the efficiency of their clinical practice and academic research, thereby enabling more precise diagnostic and therapeutic services.

Empowering AI to Drive the Restructuring of Commercialization Systems for Pharmaceutical and Medical Device Companies:The marketing of innovative drugs and medical devices is undergoing a customer-centric transformation toward compliance and specialization. While accumulating a substantial base of leading pharmaceutical companies and physician users, Zero Hypothesis has innovatively established a new model for compliant academic interaction between pharmaceutical companies and physicians. Building on this model, it helps pharmaceutical and medical device enterprises reconstruct their commercialization systems. This approach not only meets the industry’s demand for compliance but also enhances marketing efficiency and enables precise resource allocation. By providing a secure and efficient communication platform for pharmaceutical companies and physicians, it facilitates the dissemination of medical knowledge and deepens academic research, thereby comprehensively improving the ROI of pharmaceutical and medical device enterprises.

Rooted in the Local Market, Continuously Raising Barriers:Through extensive interactions and close collaboration with pharmaceutical and medical device companies as well as physicians, Zero Hypothesis has continuously optimized, iterated, refined, and accumulated its capabilities in the high-quality decomposition and reconstruction of data. On one hand, it is becoming increasingly sophisticated and mature in addressing the most challenging aspects of healthcare AIGC—namely accuracy, novelty, and comprehensiveness. On the other hand, with a focus on return on investment (ROI), it leverages AI to restructure real-world commercial application scenarios for pharmaceutical and medical device enterprises, ensuring that every stakeholder encountered and every scenario addressed during the commercial translation of innovative drugs and medical devices receives precise AI support.

Looking Globally, Embracing a Broader Horizon:Currently, Zero Hypothesis has become the preferred AIGC supplier for the Chinese subsidiaries of more than ten major global multinational pharmaceutical companies. It has accumulated experience serving over thirty leading enterprises, earning consistent recognition and acclaim from its clients. Furthermore, Zero Hypothesis has begun providing high-quality products and services to the global headquarters and overseas branches of these multinational pharmaceutical companies. This not only demonstrates the international competitiveness of Zero Hypothesis’s products but also highlights the company’s significant potential for growth in the global medical AIGC sector.

ZBJL CAPITALZero Hypothesis has been dedicated to developing products and solutions for medical AIGC since its inception. The team dares to break conventions and explore the unknown, driving efficient and professional knowledge dissemination across the entire chain of academic promotion for pharmaceutical and medical device commercialization through the deep integration of AI data technology and medical expertise. Their profound understanding and forward-thinking approach to medical AIGC, combined with years of technical accumulation, a unique business model, and responsive service efficiency, have earned the trust and collaboration of leading pharmaceutical companies both domestically and internationally. We look forward to Zero Hypothesis continuing to innovate, leveraging AI technology to help enterprises optimize content management in omnichannel marketing, thereby making academic promotion more intelligent, efficient, precise, and convenient. This will reconstruct the commercial ecosystem for innovative drugs and medical devices, facilitating the commercialization of innovative achievements.

Zero Hypothesis Information Technology Co., Ltd. was established in 2019 as a pioneering technology innovation company in China dedicated to AI-generated content (AIGC) for medical applications. Focusing on the search and generation needs of professional medical content, the company has developed a suite of leading AIGC products tailored for pharmaceutical and medical device enterprises, Grade-A tertiary hospitals, physicians, and other healthcare professionals. Its client base includes 70% of the top 20 global multinational pharmaceutical companies and tens of thousands of leading physicians from 400 premier Grade-A tertiary hospitals across China, with its product functionality and reputation far outpacing industry competitors.

Zero Hypothesis is the first company in the industry to achieve large-scale processing and production of professional medical content through end-to-end human-AI collaboration. It possesses comprehensive engineering capabilities, data capabilities, scenario implementation capabilities, and a multidisciplinary cross-functional team, with full-process independent development. Currently, it covers 10 major disease categories, over 100 specific sub-diseases, has a daily data processing capacity at the hundred-thousand level, and maintains a self-built database with tens of millions of entries. Meanwhile, Zero Hypothesis is also an industry leader in commercializing large medical models by integrating its self-built medical database, medical knowledge graph, and large language models.

ZBJL CAPITAL (Beijing) Investment Management Co., Ltd. (hereinafter referred to as “ZBJL CAPITAL”) was established in 2013, with its primary investment focus on biopharmaceuticals, next-generation information technology, and new energy. Adhering to the investment philosophy of “Being Technology-Driven and Delivering Value,” ZBJL CAPITAL emphasizes the scarce value generated by technological innovation. Rather than following trends or conforming blindly, the firm continuously identifies potential unicorn companies characterized by high technical barriers and strong core competitiveness. By empowering portfolio companies through both capital and resources, ZBJL CAPITAL supports the development of China’s technology enterprises, creates value, and contributes to the well-being of humanity and society.